2012 - 2012

  • “SynCore Biotechnology” official name registered.

  • SB01 qualified by Ministry of Economic Affairs in biotechnology and new drug development.

  • SB05 developing and marketing rights for phase 3 clinical trial in Asia Pacific were granted from Medigene AG.

  • The “Cross-Strait Cooperation Agreement on Medicine and Public Health Affairs” for SB04 was obtained from TFDA.